Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing prior literature without original data or systematic review methodology.
PubMed 36871535 · doi:10.1016/j.intimp.2023.109952
What was done
This narrative review summarizes the immunological mechanisms, historical indications (including hepatitis B, sepsis, and vaccine enhancement), and potential oncology applications of synthetic thymosin alpha 1 (thymalfasin), particularly in combination with chemoradiotherapy and immune checkpoint inhibitors.
What was found
The abstract reports no primary numerical data or effect sizes. It qualitatively reviews literature indicating that thymosin alpha 1 improves overall survival in resectable non-small cell lung cancer and liver cancer, decreases chemoradiation-induced lymphopenia and pneumonia in locally advanced non-small cell lung cancer, reduces mortality in severe sepsis, and preclinically alters macrophage polarization and attenuates checkpoint inhibitor-induced colitis.
Why it matters
It highlights the conceptual rationale for repurposing an established, safe peptide immunomodulator to potentially improve checkpoint inhibitor efficacy and mitigate treatment-related adverse effects.
Limits
The abstract describes a non-systematic narrative summary containing no original patient data or pooled quantitative analyses. No exact sample sizes, effect estimates, or study quality metrics are provided.
Cited by
- context Thymosin alpha-1 is approved as a medication throughout Europe.